results on efgartigimod for chronic inflammatory demyelinating polyneuropathy treatment
Published 11 months ago • 913 plays • Length 6:23Download video MP4
Download video MP3
Similar videos
-
5:45
advance iv results: efficacy and safety of intravenous efgartigimod in adults with primary itp
-
0:45
impact of fcrn inhibitors on igg-mediated autoimmune disorders
-
4:59
adapt analysis: efgartigimod for generalized myasthenia gravis
-
2:13
current and emerging treatment options for patients with mf who are ineligible for ruxolitinib
-
1:54
results of the morbida trial: 18f-pet for the detection of cardiac involvement in al amyloidosis
-
1:31
peroxiredoxin ii regulates exosome secretion from dermal mesenchymal stem cells via isgylation
-
1:15
the safety and efficacy of peritransplantation ruxolitinib in patients with mf
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:11
evaluating the prognostic significance of cpcs in al amyloidosis with next-generation flow cytometry
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:16
results of the restore-imi trial
-
1:58
improving diagnosis in al amyloidosis using surrogate organ tissues for biopsies
-
2:20
new prognostic markers in al amyloidosis
-
9:58
idim: equal scores – aspergillosis
-
2:23
inflammation as a predisposing factor to mpn development
-
3:51
an update on the use of fmt for the treatment of steroid- and ruxolitinib-resistant acute gvhd
-
2:56
early vs. deferred transplantation in al amyloidosis
-
1:46
are there newer tests that are better than a visual biopsy?
-
6:49
pooled fecal allogeneic microbiotherapy for gi-agvhd: results from early access program in france